Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBITDA Margin: 2012-2025

Historic EBITDA Margin for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to 17.40%.

  • Veracyte's EBITDA Margin rose 703.00% to 17.40% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.00%, marking a year-over-year increase of 1053.00%. This contributed to the annual value of 3.62% for FY2024, which is 2738.00% up from last year.
  • Per Veracyte's latest filing, its EBITDA Margin stood at 17.40% for Q3 2025, which was up 529.93% from -4.05% recorded in Q2 2025.
  • In the past 5 years, Veracyte's EBITDA Margin ranged from a high of 17.40% in Q3 2025 and a low of -114.07% during Q1 2021.
  • Over the past 3 years, Veracyte's median EBITDA Margin value was -4.05% (recorded in 2025), while the average stood at -5.82%.
  • In the last 5 years, Veracyte's EBITDA Margin tumbled by 7,643bps in 2021 and then surged by 9,158bps in 2022.
  • Veracyte's EBITDA Margin (Quarterly) stood at -18.32% in 2021, then surged by 1,157bps to -6.75% in 2022, then plummeted by 2,941bps to -36.16% in 2023, then soared by 3,968bps to 3.52% in 2024, then soared by 703bps to 17.40% in 2025.
  • Its last three reported values are 17.40% in Q3 2025, -4.05% for Q2 2025, and 2.54% during Q1 2025.